Geographically North America dominated global pharmacogenomics market because of rising demand of personalized medicines, high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and number of R&D centres in developing nations such as China, and India in this region. Among all the applications, drug discovery has the highest market share in global pharmacogenomics market.
This report identifies the global pharmacogenomics market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global pharmacogenomics market.
This report segments global pharmacogenomics market on the basis of method, therapeutic application, application, and regional market as follows:
Pharmacogenomics Market, By Method: Haplotype Analysis, and Multivariate Techniques
Pharmacogenomics Market, By Therapeutic Application: Cancer, Oncology, and Cardiovascular
The report has focused study on pharmacogenomics market by basis of application such as: Drug Safety, Tailor Treatments, and Drug Discovery
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the pharmacogenomics market. Some of the major companies’ profiles in detail are as follows:
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Johnson & Johnson
Abbott Laboratories, Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Pharmacogenomics Market– Market Forces
4.1.1. Rising demand for personalized drugs
4.1.2. Growing incidences of several infectious and non-infectious diseases
4.2.1. Higher cost of research and development
4.2.2. Finding the association between a genetic marker and a phenotypic drug response
4.3.1. Emerging economies
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Pharmacogenomics Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Pharmacogenomics Market, By Method
6.1. Haplotype Analysis
6.2. Multivariate Techniques
7. Pharmacogenomics Market, By Therapeutic Application
8. Pharmacogenomics Market, By Application
8.1. Drug Safety
8.2. Tailor Treatments
8.3. Drug Discovery
9. Pharmacogenomics Market, By Geography
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.4. Rest of the World (RoW)
9.4.2. Rest of RoW
10. Pharmacogenomics – Market Entropy
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
11.1. Bristol-Myers Squibb Company
11.2. F. Hoffmann-La Roche Ltd.
11.3. Merck & Co., Inc.
11.4. Johnson & Johnson
11.5. Abbott Laboratories, Inc.
11.6. Affymetrix, Inc.
11.7. AstraZeneca plc
11.8. Bayer AG
11.9. GE Healthcare
11.10. GlaxoSmithKline plc
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12.3. Research Methodology
12.5. Compilation of Expert Insights